AusperBio

Executive Summary

AusperBio is a Phase II clinical-stage biopharmaceutical company pioneering a curative treatment for hepatitis B virus (HBV) through its proprietary Med-Oligo™ antisense oligonucleotide (ASO) platform. The platform combines potent ASO design with targeted delivery technologies to silence disease-driving genes, offering potential across viral infections, metabolic disorders, genetic conditions, and immune diseases. Founded in 2019 and headquartered in Cambridge, MA, AusperBio is privately held and has advanced its lead HBV candidate into Phase II trials, positioning it as a key player in the race for an HBV functional cure. AusperBio’s near-term value is driven by the clinical progress of its HBV program. The company is expected to report Phase II interim data in the second half of 2026, which could de-risk the program and attract partnership interest. Additionally, the platform’s versatility supports pipeline expansion into metabolic and genetic diseases, with potential IND filings in 2027. While the company remains early-stage and private, its focused approach to ASO therapeutics and validated delivery system provide a differentiated path in the highly competitive HBV landscape.

Upcoming Catalysts (preview)

• H2 2026Phase II interim data readout for HBV candidate55% success
• 2027IND filing for a second indication (e.g., metabolic disease)40% success
• H2 2026Series B or partnership financing round60% success